News

State-of-the-Art Compounding Pharmacy Will Accelerate Early Development Programs

A collaboration to accelerate the development of a lead COVID-19 drug candidate into human clinical trials announced by Quotient Sciences and CytoAgents.

We are confronting an unprecedented crisis caused by the COVID-19 viral outbreak. Inevitably this pandemic will result in significant impact on society and interruption to businesses. None of us have experienced anything equivalent to this situation, and it is changing rapidly on a day-to-day basis.

As a leading business in the healthcare industry, we understand the gravity of the situation and the challenge ahead of us. The management of Quotient Sciences has been closely monitoring the ongoing COVID-19 situation and taking steps to limit any potential impact it could have on our trial subjects, our staff, our customers, our community, and our business.

The Faculty of Engineering and School of Pharmacy, at the University of Nottingham, are delighted to announce the receipt of an MRC Confidence in Concepts grant. Working in collaboration with Quotient Sciences, Added Scientific and AstraZeneca, the grant will translate towards clinical applications some of the advances made at Nottingham in the 3D printing of pharmaceutical dosage forms.

Quotient Sciences, today announced plans to present on the latest Tufts CSDD White Paper assessing the timeline reductions and multi-million dollar cost savings of Translational Pharmaceutics® at Biotech Showcase 2020™, to be held January 13-15, during the most important week in healthcare at the Hilton San Francisco Union Square.